Table 2.
Summary of initial antifungal treatment in patients with proven and suspected invasive candidiasis
| Antifungal treatment | SAT for proven invasive candidiasis N = 291 |
SAT for suspected invasive candidiasis N = 544 |
|---|---|---|
| Monotherapy | 287 (98.6 %) | 541 (99.5 %) |
| Polyenes | 6 (2.1 %) | 6 (1.1 %) |
| Amphotericin B deoxycholate | 0 | 3 |
| Liposomal amphotericin B | 4 | 3 |
| Amphotericin B lipid complex | 2 | 0 |
| Azoles | 99 (34.5 %) | 248 (45.8 %) |
| Fluconazole | 99 | 244 |
| Voriconazole | 0 | 4 |
| Echinocandin | 182 (63.4 %) | 287 (53.0 %) |
| Caspofungin | 160 | 252 |
| Micafungin | 20 | 34 |
| Anidulafungin | 0 | 1 |
| Flucytosine | 0 | 0 |
| Combination therapy | 4 | 3 |
| Liposomal amphotericin B and flucytosine | 0 | 2 |
| Caspofungin and fluconazole | 2 | 0 |
| Caspofungin and voriconazole | 1 | 0 |
| Caspofungin and flucytosine | 1 | 0 |
| Amphotericin B deoxycholate and micafungin | 0 | 1 |
The results are given as n (%)
SAT systemic antifungal therapy